ABT · 10-Q · 2026Q2 · Full report

Order Backlog and Book-to-Bill

ABBOTT LABORATORIES · 2026-07-28 · Importance 56 · Surprise 24

Abbott had $6.2 billion of estimated future revenue tied to unsatisfied or partially unsatisfied performance obligations in the Diagnostic Products segment as of June 30, 2026. These obligations primarily relate to future product sales under contracts with minimum purchase commitments, extended warranties or service arrangements for previously sold equipment, and remote monitoring services for implanted devices. The disclosed obligations indicate contracted demand extending beyond the current reporting period, although amounts for Medical Devices and Established Pharmaceutical Products are not provided in the filing excerpt.